Clinical Trials Browser

Phase 3 × Oxaliplatin × 30 days × Clear all

Resectable Colon Cancer

Metastatic Adenocarcinoma of the Pancreas

Colonic Neoplasms, Rectal Neoplasms

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Pancreatic Neoplasms

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

Rectal Neoplasms

Colonic Neoplasms

Colorectal Neoplasms

Colorectal Neoplasms

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Locally Advanced Gastric or Gastroesophageal Junction Cancer

HER2-positive Gastric Cancer

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Lymphoma, Large B-Cell, Diffuse

Pancreatic Neoplasms

Lymphoma, Large B-Cell, Diffuse

Colorectal Neoplasms

Adenocarcinoma Of Esophagus

Colorectal Neoplasms

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

Adenocarcinoma, Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

NAPOLI 3

KANDLELIT-012

GLOW

HERIZON-GEA-01

MK-3475-C66

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NEO-RT

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

OrigAMI-2

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Beacon-BTC

EPCORE DLBCL-4

LAP100

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

MOUNTAINEER-03

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

HARMONi-GI3

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

LUCERNA

STAR-221

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL